Drug
AZD5305 clinical trials
Also written Saruparib and AZD5305.
- studies test it
- 15
- open now
- 9
- in phase 3
- 4
- first study started
- 2019
Keep track of what changes. Save the AZD5305 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 5
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 3
AstraZeneca (12) · Abramson Cancer Center at Penn Medicine (1) · OHSU Knight Cancer Institute (1) · University of Leeds (1)
Often tested with
Tested in the same studies.
Olaparib (2) · Furosemide (1) · Apalutamide (1) · Darolutamide (1) · Itraconazole (1) · Puxitatug samrotecan (1) · Rilvegostomig (1) · Polymerase Theta Helicase Inhibitor AZD4956 (1)
Studies
Open first, then newest update. How each study uses AZD5305 is read from its arms, and is right about nine times in ten.
Testing it · 15
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)RecruitingPhase 3AstraZenecaNCT07711002Written as Saruparib
- A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationRecruitingPhase 3AstraZenecaNCT06952803Written as Saruparib
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesRecruitingPhase 1/2AstraZenecaNCT05123482Written as AZD8205 and AZD5305 (saruparib)
- Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid TumoursRecruitingPhase 1/2AstraZenecaNCT07446855Written as Saruparib
- Saruparib in HRDsig+ Solid TumorsNot yet recruitingPhase 2Abramson Cancer Center at Penn MedicineNCT07832630Written as Saruparib
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690Written as Saruparib
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751Written as Saruparib (AZD5305)
- AZD5305 hADME in Patients With Advanced Solid MalignanciesRecruitingPhase 1AstraZenecaNCT06713369Written as Saruparib (AZD5305)
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingPhase 1University of LeedsNCT04550104Written as AZD5305
- Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of SaruparibActive, not recruitingPhase 1AstraZenecaNCT06899061Written as Saruparib
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerActive, not recruitingPhase 1/2AstraZenecaNCT05367440Written as AZD5305
- Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsActive, not recruitingPhase 3AstraZenecaNCT06120491Written as Saruparib
- A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.CompletedPhase 1AstraZenecaNCT05938270Written as Saruparib (AZD5305)
- A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian CancerWithdrawnPhase 1/2AstraZenecaNCT07060365Written as Saruparib
- Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid MalignanciesCompletedPhase 1AstraZenecaNCT05573724Written as AZD5305
Given in every arm · 4 — AZD5305 is usual care beside what is tested
- Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsRecruitingPhase 1/2AstraZenecaNCT05797168Written as Saruparib
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyRecruitingPhase 2SWOG Cancer Research NetworkNCT06769126Written as Saruparib
- A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer DrugsActive, not recruitingPhase 1/2AstraZenecaNCT07336446Written as AZD5305
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingPhase 1/2AstraZenecaNCT04644068Written as AZD5305
Codes
What other systems call AZD5305 · ClinicalTrials.gg INT001893
- MeSH (NLM) C000722772AZD5305One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722772 | AZD5305 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.